Department of Neurology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Department of Public Health and Community Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Headache. 2022 Sep;62(8):1046-1052. doi: 10.1111/head.14374. Epub 2022 Aug 25.
Coronavirus disease 2019 (COVID-19) vaccine-related side effects are a key concern with the emergence of various types of vaccines in the market. We aimed to assess the frequency and characteristics of headache following different types of COVID-19 vaccines.
Fully vaccinated people were recruited by a convenience sample through an online survey from September 1 to December 1, 2021. Detailed analysis of headache following vaccination was investigated. Participants with a history of pre-existing headaches were telephone interviewed by a neurologist to ascertain the type of headache.
A total of 1372 participants participated (mean age 32.9 ± 11.1). The highest frequency of headache was reported with the adenoviral vector type (302/563, 53.6%), followed by mRNA vaccines (129/269, 48%) and then the inactivated type (188/540, 34.8%). Recipients of the adenoviral vector type had a significantly longer latency between vaccination and the headache onset (median 8 h [5:12]) than recipients of the inactivated type (median 4 h [2:8], p < 0.001). Headache intensity was significantly higher with the adenoviral vector type (median 6 [5:8]) than with the inactivated type (median 5 [4:7], p < 0.001). Adenoviral vector vaccines would increase the likelihood of headache by 2.38 times more than inactivated vaccines (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.83-3.04, p < 0.001). Female sex and thyroid disease were significantly associated with headache related to COVID-19 vaccines (OR 1.52, 95% CI 1.16-1.99; OR 3.97, 95% CI 1.55-10.2, respectively).
Recipients of the COVID-19 vaccine should be counseled that they may experience headaches, especially after the adenoviral vector type. However, the intensity of such headache is mild to moderate and can resolve within a few days. Based on the current study design and the potential recall bias, these results may not be generalizable and should be preliminary.
随着市场上各种类型的 COVID-19 疫苗的出现，与 COVID-19 疫苗相关的副作用是一个关键问题。我们旨在评估不同类型的 COVID-19 疫苗接种后头痛的频率和特征。
通过 2021 年 9 月 1 日至 12 月 1 日的在线调查，通过便利抽样招募了完全接种疫苗的人群。详细分析了接种疫苗后的头痛情况。对有预先存在的头痛史的参与者进行了电话采访，由神经病学家确定头痛类型。
共有 1372 名参与者（平均年龄 32.9±11.1）。报告头痛的频率最高的是腺病毒载体类型（302/563，53.6%），其次是 mRNA 疫苗（129/269，48%），然后是灭活类型（188/540，34.8%）。腺病毒载体型接种者头痛发作的潜伏期明显长于灭活型（中位数 8 小时[5:12]）（p<0.001）。腺病毒载体型的头痛强度明显高于灭活型（中位数 6[5:8]）（p<0.001）。腺病毒载体疫苗比灭活疫苗使头痛的可能性增加 2.38 倍（优势比[OR]2.38，95%置信区间[CI]1.83-3.04，p<0.001）。女性和甲状腺疾病与 COVID-19 疫苗相关的头痛显著相关（OR 1.52，95%CI 1.16-1.99；OR 3.97，95%CI 1.55-10.2）。
接种 COVID-19 疫苗的人应被告知，他们可能会出现头痛，尤其是在接种腺病毒载体类型后。然而，这种头痛的强度是轻度到中度的，并可以在几天内解决。基于目前的研究设计和潜在的回忆偏差，这些结果可能不具有普遍性，应该是初步的。
